Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.

ABSTRACT:

Lessons learned

Advanced germ cell tumors are aggressive and associated with poor prognosis. Pembrolizumab was overall well tolerated in 12 heavily pretreated patients. Three patients had radiographic stable disease that lasted for 10.9 months, 5.5 months, and 4.5 months, respectively. Published data of immunotherapeutic agents in patients with advanced germ cell tumors are confirmed. The limited antitumor activity of immunotherapy in germ cell tumors is, at least partially, attributed to tumor biology (low tumor mutational burden; low PD-1 expression) and other poor-risk features. Tumor profiling to understand the mechanisms of resistance to pembrolizumab and innovative clinical trials that may include immunotherapy are warranted.

Background

Advanced germ cell tumors are as

SUBMITTER: Tsimberidou AM 

PROVIDER: S-EPMC8265349 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature